Interleukin 6 News and Research

RSS

Interleukin-6 (IL-6) is a protein that in humans is encoded by the "IL6" gene. IL-6 is an interleukin that acts as both a pro-inflammatory and anti-inflammatory cytokine. It is secreted by T cells and macrophages to stimulate immune response to trauma, especially burns or other tissue damage leading to inflammation.

A Mediterranean ingredient gave gluten-free pasta an unexpected upgrade

Researchers developed carob-enriched gluten-free tagliatelle that increased dietary fiber and antioxidant activity while reducing starch digestibility and improving pasta structure. A 20% carob substitution provided the best overall balance of functional properties, texture, and consumer acceptance, although clinical health benefits remain to be established.

17 Aug 2026

IL-6 receptor blockers show promise for preventing MOGAD relapses

An international study led by Mayo Clinic researchers has identified interleukin-6 (IL-6) receptor blockers as a promising option for preventing relapses in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). MOGAD is a rare autoimmune neurological disorder that can cause vision loss, paralysis and other serious neurological complications.

6 Aug 2026

Ten-million-person study links semaglutide to lower COVID-19 mortality

Researchers analyzing claims from more than 10.1 million commercial insurance and Medicare Advantage enrollees found that semaglutide use was associated with a 49% lower adjusted hazard of COVID-19-related death. The observational findings corroborate earlier SELECT trial results but do not establish causation, making further prospective research essential.

30 Jul 2026

Evidence shows artificial sweeteners cannot be judged as a single group

This narrative review found that non-nutritive artificial sweeteners have compound-specific and context-dependent associations with gut microbiota, metabolism, and health-related outcomes. Evidence does not support treating all sweeteners as uniformly harmful or safe, with human findings often limited or inconsistent.

23 Jul 2026

Thymulin curbs age-related inflammation and slows breast tumors in mice

Thymulin reduced age-associated inflammatory myeloid cells and slowed breast-tumor growth in aged mice by suppressing NF-κB signaling. The peptide also restored anti-PD-L1 responsiveness in aged mouse models, while human cell and tumor data supported an age-linked inflammatory myeloid profile.

23 Jul 2026

Five epigenetic clocks reveal shared and distinct signals of aging

Researchers linked five epigenetic clocks to distinct blood gene-expression patterns and biological pathways in 3,227 Health and Retirement Study participants. TAGS derived from these patterns often showed stronger associations with frailty, functional measures, morbidity, and mortality than their parent clocks, although further validation is needed.

22 Jul 2026

ddPCR and NGS for viral surveillance in antiviral drug development

hVIVO explains how ddPCR and NGS support viral surveillance in antiviral trials, from detection and quantification to resistance sequencing.

From hVIVO 20 Jul 2026

Micro and nanoplastics in the blood linked to increased heart attack risk factors

People who have suffered a serious heart attack had higher levels of micro and nanoplastics in their blood, compared to patients diagnosed with chronic ischemic heart disease and those who have normal blood vessels supplying the heart, according to a study published in the European Heart Journal today (Wednesday).

14 Jul 2026

Bifidobacterium-based oral vaccine enhances anti-tumor immunity in clinical study

A novel oral vaccine platform using genetically engineered Bifidobacterium could enhance anti-tumor immunity.

14 Jul 2026

GLP-1RAs linked to lower risk of amputation in diabetes with PAD

Research indicates GLP-1RAs may decrease limb complications in type 2 diabetes with PAD, though more randomized studies are required to confirm efficacy.

10 Jul 2026

Severe gum disease linked to early kidney function decline

A growing body of research suggests that the effects of periodontitis extend far beyond the mouth.

2 Jul 2026

Reversing macrophage metabolism may improve cancer immunotherapy outcomes

Tumor-associated macrophages (TAMs) are among the most abundant immune cells in the tumor microenvironment.

1 Jul 2026

Anti-inflammatory molecule reduces excessive alcohol consumption in female mice

The drugs that keep rheumatoid arthritis in check may one day help people stop drinking. A new Scripps Research study shows that an anti-inflammatory molecule, already approved by the U.S. Food and Drug Administration to treat autoimmune diseases, reduces excessive alcohol consumption in alcohol-dependent female mice.

29 Jun 2026

Melatonin dampens fetal membrane inflammation linked to preterm birth

Melatonin reduced infection-related inflammation in human fetal membranes in an ex vivo model. The study suggests that this effect works partly through melatonin receptors and by suppressing the TLR4/MyD88/NF-κB pathway.

28 Jun 2026

Exercise, not liraglutide alone, drives vascular gains after obesity-related weight loss

A prespecified secondary analysis of the S-LiTE trial found that regular exercise reduced carotid artery wall thickness and circulating levels of inflammatory cytokines in adults with obesity who had already achieved substantial diet-induced weight loss. Liraglutide alone did not significantly improve these vascular or inflammatory markers, while exercise plus liraglutide also improved endothelial function biomarkers.

25 Jun 2026

Eating 90 g of wholegrains daily linked to lower breast cancer risk

Research indicates that long-term wholegrain intake per Nordic guidelines is associated with reduced breast cancer risk, emphasizing food type differences.

24 Jun 2026

Researchers identify molecular pathway that delays diabetic wound healing

Diabetic foot ulcer (DFU) is one of the most serious complications of diabetes and a major cause of lower-limb amputation.

23 Jun 2026

Three-drug strategy forces pancreatic tumors into lasting regression

A triple-targeted preclinical therapy combining daraxonrasib, afatinib, and SD36 drove durable pancreatic cancer regression by blocking KRAS/RAS, EGFR/HER2, and STAT3 signaling. The approach prevented treatment resistance across mouse and human tumor-derived models, but remains preclinical and requires more clinically suitable drug combinations before human testing.

2 Jun 2026

How do everyday spices help protect the heart?

A Nutrition Reviews supplement article reviewed controlled studies showing that culinary spice and herb blends may improve selected cardiometabolic risk markers, including post-meal triglycerides, insulin responses, inflammation, endothelial function, and 24-hour blood pressure. The review also highlighted exploratory evidence that spices and herbs may influence immune-cell activity, circulating phytochemical metabolites, and gut bacterial composition, while emphasizing the need for longer and more diverse studies.

27 May 2026

New guidelines for identifying and treating high-risk IEC-HS patients

Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of hematologic malignancies, offering durable responses for patients with otherwise refractory disease. However, its clinical success is accompanied by a spectrum of immune-related toxicities, which remain a major challenge in practice.

15 May 2026